2 recruiting, 2 terminated, 1 withdrawn. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Endometrial: new trials by email Literature Review of Endometrial trials Research Report on Endometrial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors TS-104 - NSCLC (Non-small Cell Lung Cancer), HNSCC | Phase 1 | Recruiting | TwoStep Therapeutics, Inc. | 74 | 2026-09-02 | 2026-09-30 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer Avutometinib, defactinib, Everolimus - Phase IB, Avutometinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 31 | 2026-05-13 | 2026-06-29 |
| A Study of SGN-MesoC2 in Advanced Solid Tumors PF-08052666 - Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 19 | 2024-08-02 | 2026-07-07 |
| Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. PF-07224826, Fulvestrant - Breast Cancer, Ovarian Cancer | Phase 1 | Withdrawn | Pfizer | 2024-01-15 | 2023-11-08 | |
| Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) Temsirolimus, Irinotecan, Irinotecan + capecitabine - Advanced Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Western Regional Medical Center | 33 | 2015-04-01 | 2018-07-02 |
Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (3) · Colorectal Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Liposarcoma (1) · Lung Neoplasms (1) · Mesothelioma (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Lung Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4)
Capecitabine (1) · Everolimus (1) · Fulvestrant (1) · Irinotecan (1) · Nivolumab (1) · defactinib (1) · temsirolimus (1)
M.D. Anderson Cancer Center (1) · Pfizer (1) · Seagen, a wholly owned subsidiary of Pfizer (1) · TwoStep Therapeutics, Inc. (1) · Western Regional Medical Center (1)
United States (4) · Canada (1)
Cynthia Lynch, MD (1) · Jordan Waypa, MSN, FNP (1) · Shannon N Westin, MD (1)